Current status is Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

119th CONGRESS

1st Session

H. R. 1672

1. Short title
2. Amendment to definition of qualifying single source drug

1. Short title

This Act may be cited as the "Maintaining Investments in New Innovation Act".

2. Amendment to definition of qualifying single source drug

Section 1192(e) of the Social Security Act (42 U.S.C. 1320f–1(e)) is amended—

(1) - in paragraph (1)(A)(ii), by inserting "(or, in the case of an advanced drug product (as defined in paragraph (4)), 11 years)" after "7 years"; and

(2) Advanced drug product defined - by adding at the end the following new paragraph:

(4) Advanced drug product defined - For purposes of paragraph (1)(A)(ii), the term advanced drug product means a drug that incorporates or utilizes a genetically targeted technology (as defined in section 529A(c)(2) of the Federal Food, Drug, and Cosmetic Act) that may result in the modulation (including suppression, up-regulation, or activation) of the function of a gene or its associated gene product.

119-HR1672

Maintaining Investments in New Innovation Act

119th CONGRESS

1st Session

H. R. 1672

1. Short title

2. Amendment to definition of qualifying single source drug